ArticleApplied microbiology and biotechnology2026
Real-time NMR monitoring of HMF biotransformation by Ectopseudomonas oleovorans CECT 5344 R1D.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This research identifies Ectopseudomonas oleovorans CECT 5344 R1D as a novel and highly efficient biocatalyst for the sustainable production of 5-hydroxymethyl-2-furancarboxylic acid (HMFCA). By employing benchtop Nuclear Magnetic Resonance (NMR) spectroscopy with a recirculating flow system, we achieved real-time monitoring and a detailed stoichiometric characterisation of the 5-hydroxymethylfurfural (HMF) detoxification pathway. This work contributes to the specialised field of real-time metabolic tracking of living biocatalysts, a niche where in situ NMR data is still scarce compared to end-point analytical methods. Our findings demonstrate that this strain, while not utilising HMF for biomass growth, maintains exceptional metabolic stability and quantitative molar yields over 125 h of operation, requiring significantly lower cell densities than other reported Pseudomonas strains. The in-line NMR setup enabled the definitive identification of 2,5-bis(hydroxymethyl)furan (BHMF) as a transient intermediate, clarifying previous metabolic misidentifications and revealing a highly specific, non-consuming "cell factory" behaviour. Furthermore, the system allowed for the assessment of bacterial tolerance thresholds and the exploration of the enzymatic substrate scope against other environmentally relevant aldehydes. This work underscores the synergy between a robust, living biocatalyst and a precise monitoring platform, providing an optimised workflow for bioprocess development in sustainable aldehyde valorisation. KEY POINTS: • Real-time monitoring of a microbial process via in-line benchtop NMR. • Versatile biodetoxification of various natural and synthetic aldehydes. • Green chemistry alternative to petrochemicals using renewable feedstocks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.